[08a] In one aspect, there is provided a pharmaceutical composition comprising:

a) about 10% to 30% of a non-steroidal anti-inflammatory drug (NSAID) by weight of the pharmaceutical composition;
b) about 20% to about 50% of a hard fat by weight of the pharmaceutical composition;
c) about 10% to about 30% of a polyether fatty acid ester by weight of the pharmaceutical composition, and
d) about 5% to about 15% of a polyethylene glycol (PEG) polymer by weight of the pharmaceutical composition.

[08b] In one aspect, there is provided use of a pharmaceutical composition according as defined herein in the manufacture of a medicament for the treatment of a chronic inflammation.

[08c] In one aspect, there is provided use of a pharmaceutical composition as defined herein for the treatment of a chronic inflammation.

Other aspects of the present specification disclose a method of preparing a pharmaceutical composition, the method comprising the step of contacting a therapeutic compound with a pharmaceutically-acceptable adjuvant under conditions which allow the formation of the pharmaceutical composition. Other aspects of the present specification disclose a method of preparing a pharmaceutical composition, the method comprising the steps: a) contacting a pharmaceutically-acceptable solvent with a therapeutic compound under conditions which allow the therapeutic compound to dissolve in the pharmaceutically-acceptable solvent, thereby forming a solution, wherein the therapeutic compound has anti-inflammatory activity, and b) contacting the solution formed in step (a) with a pharmaceutically-acceptable adjuvant under conditions which allow the formation of the pharmaceutical composition. In other aspects, the method of preparing disclosed herein further comprises c) removing the pharmaceutically-acceptable solvent from the pharmaceutical composition.

[09] Other aspects of the present specification disclose a pharmaceutical composition, the pharmaceutical composition made according to a method comprising the step of contacting a therapeutic compound with a pharmaceutically-acceptable adjuvant under conditions which allow the formation of the pharmaceutical composition. Other aspects of the present specification disclose a pharmaceutical composition, the pharmaceutical composition made according to a method comprising the steps: a) contacting a pharmaceutically-acceptable solvent with a therapeutic compound under conditions which allow the therapeutic compound to dissolve in the pharmaceutically-acceptable solvent, thereby forming a solution, wherein the therapeutic compound has anti-inflammatory activity, and b) contacting the solution formed in step (a) with a pharmaceutically-acceptable adjuvant under conditions which allow the formation of the pharmaceutical composition. In other aspects, the method of making a pharmaceutical composition disclosed herein further comprises c) removing the pharmaceutically-acceptable solvent from the pharmaceutical composition.

[010] Other aspects of the present specification disclose a method of treating an individual with a chronic inflammation, the method comprising the step of administering to the individual in need thereof a pharmaceutical composition disclosed herein, wherein administration results in a reduction in a symptom associated with the chronic inflammation, thereby treating the individual.

[011] Other aspects of the present specification disclose a use of a pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a chronic inflammation.

[012] Other aspects of the present specification disclose a use of a pharmaceutical composition disclosed herein for the treatment of a chronic inflammation.

CLAIMS

1. A pharmaceutical composition comprising:

   a) about 10% to 30% of a non-steroidal anti-inflammatory drug (NSAID) by weight of the pharmaceutical composition;

   b) about 20% to about 50% of a hard fat by weight of the pharmaceutical composition;

   c) about 10% to about 30% of a polyether fatty acid ester by weight of the pharmaceutical composition, and

   d) about 5% to about 15% of a polyethylene glycol (PEG) polymer by weight of the pharmaceutical composition.

2. The pharmaceutical composition according to Claim 1, wherein the NSAID is about 20% to about 30% by weight of the pharmaceutical composition.

3. The pharmaceutical composition according to Claim 1 or Claim 2, wherein the NSAID is in an amount from about 25% to about 30% by weight of the pharmaceutical composition.

4. The pharmaceutical composition according to any one of Claims 1-3, wherein the NSAID is a non-selective cyclo-oxygenase (COX) inhibitor, a selective cyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2) inhibitor or a combination thereof.

5. The pharmaceutical composition according to any one of Claims 1-4, wherein the NSAID comprises a salicylate derivative NSAID, a p-amino phenol derivative NSAID, a propionic acid derivative NSAID, an acetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamic acid derivative NSAID or a combination thereof.

6. The pharmaceutical composition according to Claim 5, wherein the propionic acid derivative NSAID comprises an Alminoprofen, a Benoxaprofen, a Dexketoprofen, a Fenoprofen, a a Flurbiprofen, an Ibuprofen, an Indoprofen, a Ketoprofen, a Loxoprofen, a Naproxen, an Oxaprozin, a Pranoprofen, or a Suprofen.

7. The pharmaceutical composition according to Claim 6, wherein the propionic acid derivative NSAID is a pharmaceutically-acceptable form of an Ibuprofen.

8. The pharmaceutical composition according to any one of Claims 1-7, wherein the hard fat is in an amount from about 30% to about 50% by weight of the pharmaceutical composition.

9. The pharmaceutical composition according to Claim 8, wherein the hard fat is in an amount from about 35% to about 45% by weight of the pharmaceutical composition.

10. The pharmaceutical composition according to any one of Claims 1-9, wherein the hard fat has a melting point of about 40°C to about 46°C.

11. The pharmaceutical composition according to any one of Claims 1-10, wherein the hard fat comprises a triglyceride or a triester of glycerol.

12. The pharmaceutical composition according to Claim 11, wherein the triglyceride comprises a mixture of saturated C_{10}-C_{18} triglycerides having a melting point of between 41°C to 45°C.

13. The pharmaceutical composition according to Claim 11 or Claim 12, wherein the triglyceride comprises a mixture of saturated C_{10}-C_{18} triglycerides having a melting point of about 43°C.

14. The pharmaceutical composition according to any one of Claims 1-13, wherein the polyether fatty acid ester is in an amount from about 15% to about 25% by weight of the pharmaceutical composition.

15. The pharmaceutical composition according to Claim 14, wherein the polyether fatty acid ester comprises a mono-fatty acid ester of a polyether, a di-fatty acid ester of a polyether, or a tri-fatty acid ester of a polyether, or any combination thereof.

16. The pharmaceutical composition according to Claim 14 of Claim 15, wherein the polyether fatty acid ester is glyceryl monolinoleate.

17. The pharmaceutical composition according to any one of Claims 1-16, wherein the PEG polymer is in an amount from about 8% to about 15% by weight of the pharmaceutical composition.

18. The pharmaceutical composition according to any one of Claims 1-16, wherein the PEG polymer is in an amount from about 7% to about 13% by weight of the pharmaceutical composition.

19. The pharmaceutical composition according to Claim 17 or Claim 18, wherein the pharmaceutically-acceptable PEG polymer is in an amount from about 8% to about 12% by weight of the pharmaceutical composition.

20. The pharmaceutical composition according to Claim 19, wherein the PEG polymer is in an amount from about 9% to about 11% by weight of the pharmaceutical composition.

21. The pharmaceutical composition according to any one of Claims 1-20, wherein the PEG polymer is a liquid PEG polymer.

22. The pharmaceutical composition according to any one of Claims 1-21, wherein the pharmaceutically-acceptable PEG polymer is less than about 2,000 g/mol.

23. The pharmaceutical composition according to Claim 21 or Claim 22, wherein the liquid PEG polymer is a PEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, a PEG 700, a PEG 800, a PEG 900, a PEG 1000, or a combination thereof.

24. The pharmaceutical composition according to any one of Claims 1-24, further comprises about 5% to about 15% propylene glycol (PPG) polymer.

25. The pharmaceutical composition according to Claim 24, wherein the PPG polymer is in an amount from about 8% to about 15% by weight of the pharmaceutical composition.

26. The pharmaceutical composition according to Claim 24, wherein the PPG polymer is in an amount from about 7% to about 13% by weight of the pharmaceutical composition.

27. The pharmaceutical composition according to Claim 25 or Claim 26, wherein the pharmaceutically-acceptable PPG polymer is in an amount from about 8% to about 12% by weight of the pharmaceutical composition.

28. The pharmaceutical composition according to Claim 27, wherein the PPG polymer is in an amount from about 9% to about 11% by weight of the pharmaceutical composition.

29. The pharmaceutical composition according to any one of Claims 24-28, wherein the PPG polymer is a liquid PPG polymer.

30. The pharmaceutical composition according to any one of Claims 24-29, wherein the pharmaceutically-acceptable PPG polymer is less than about 2,000 g/mol.

31. The pharmaceutical composition according to Claim 29 or Claim 30, wherein the liquid PPG polymer is a PPG 100, a PPG 200, a PPG 300, a PPG 400, a PPG 500, a PPG 600, a PPG 700, a PPG 800, a PPG 900, a PPG 1000, or a combination thereof.

32. Use of a pharmaceutical composition according as defined in any one of Claims 1-31 in the manufacture of a medicament for the treatment of a chronic inflammation.

33. Use of a pharmaceutical composition as defined in any one of Claims 1-31 for the treatment of a chronic inflammation.

34. The use according to Claim 32 or Claim 33, wherein the chronic inflammation is associated with acne, acid reflux/heartburn, age related macular degeneration (AMD), allergy, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma. atherosclerosis, autoimmune disorders, balanitis, blepharitis, bronchiolitis, bronchitis, a bullous *pemphigoid*, *burn*, *bursitis*, *cancer*, *cardiac arrest*, *carditis*, *celiac disease*, *cellulitis*, *cervicitis*, cholangitis, cholecystitis, chorioamnionitis, chronic obstructive pulmonary disease (COPD), cirrhosis, colitis, congestive heart failure, conjunctivitis, cyclophosphamide-induced cystitis, cystic fibrosis, cystitis, common cold, dacryoadenitis, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcer, digestive system disease, eczema, emphysema, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, hidradenitis suppurativa, Huntington's disease, hyperlipidemic pancreatitis, hypertension, ileitis, infection, inflammatory bowel disease, inflammatory cardiomegaly, inflammatory neuropathy, insulin resistance, interstitial cystitis, interstitial nephritis, iritis, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, mastitis, mastoiditis, meningitis, metabolic syndrome (syndrome X), a migraine, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, non-alcoholic steatohepatitis, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvic inflammatory disease, pemphigus vularis, pericarditis, peritonitis, pharyngitis, phlebitis, pleuritis, pneumonitis, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, pylephlebitis, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, spastic colon, stenosis, stomatitis, stroke, surgical complication, synovitis, tendonitis, tendinosis, tenosynovitis, thrombophlebitis, tonsillitis, trauma, traumatic brain injury, transplant rejection, trigonitis, tuberculosis, tumor, urethritis, ursitis, uveitis, vaginitis, vasculitis, or vulvitis.

35. The use according to Claim 32 or Claim 33, wherein the chronic inflammation is a tissue inflammation or a systemic inflammation.

36. The use according to Claim 32 or Claim 33, wherein the chronic inflammation is an auto-immune disease or a non-autoimmune disease.

37 The use according to Claim 32 or Claim 33, wherein the chronic inflammation is associated with an arthritis, a myopathy, a vasculitis, a skin disorder, a gastrointestinal disorder, a cardiovascular disease, a cancer, a pharmacologically-induced inflammation, an infection, a tissue or organ injury, a transplant rejection, a graft-versus-host disease, a Th1-mediated inflammatory disease, a chronic neurogenic inflammation.

CLAIMS

1. A pharmaceutical composition comprising: a) a therapeutic compound, wherein the therapeutic compound has an anti-inflammatory activity; b) a pharmaceutically-acceptable solvent comprises a pharmaceutically-acceptable glycol ether; and c) a pharmaceutically-acceptable adjuvant comprises a pharmaceutically-acceptable lipid, wherein the ratio of the pharmaceutically-acceptable solvent to pharmaceutically-acceptable adjuvant is in a range from about 0:1 to about 1:25.

2. The pharmaceutical composition according to Claim 1, wherein the pharmaceutically-acceptable glycol ether comprises diethylene glycol monomethyl ether (2-(2-methoxyethoxy)ethanol), diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol), diethylene glycol monopropyl ether (2-(2-propoxyethoxy)ethanol), diethylene glycol monoisopropyl ether (2-(2-isopropoxyethoxy)ethanol), diethylene glycol mono-n-butyl ether (2-(2-butoxyethoxy)ethanol), or any combination thereof.

3. The pharmaceutical composition according to Claim 1, wherein the pharmaceutically-acceptable lipid comprises a pharmaceutically-acceptable glycerolipid, a pharmaceutically-acceptable glycol fatty acid ester, a pharmaceutically-acceptable polyether fatty acid ester, a mixture of pharmaceutically-acceptable lipids, or any combination thereof.

4. The pharmaceutical composition according to Claim 3, wherein the pharmaceutically-acceptable glycol fatty acid ester is a monoester of a glycol, a diester of a glycol, or a triester of a glycol.

5. The pharmaceutical composition according to Claim 3, wherein the pharmaceutically-acceptable glycol fatty acid ester is a ethylene glycol fatty acid ester, a diethylene glycol fatty acid ester, a propylene glycol fatty acid ester, and a dipropylene fatty acid ester.

6. The pharmaceutical composition according to Claim 3, wherein the pharmaceutically-acceptable polyether fatty acid ester is a mono-fatty acid ester of a polyether, a di-fatty acid ester of a polyether, or a tri-fatty acid ester of a polyether.

7. The pharmaceutical composition according to Claim 3, wherein the pharmaceutically-acceptable polyether fatty acid ester includes a PEG fatty acid ester, a PEG glyceryl fatty acid, a PEG fatty acid ester glyceride, a PPG fatty acid ester, a PPG glyceryl fatty acid, or a PPG fatty acid ester glyceride.

8. The pharmaceutical composition according to Claim 3, wherein the mixture of pharmaceutically-acceptable lipids is a mixture of mono-, di-, and triglycerides and PEG fatty acid esters having a melting point of about 39°C.

9. The pharmaceutical composition according to Claim 3, wherein the mixture of pharmaceutically-acceptable lipids is a mixture of pharmaceutically-acceptable lipids includes mono-, di-, and triglycerides and PEG fatty acid esters having a melting point of about 43°C.

10. A solid pharmaceutical composition comprising: a) a non-steroidal anti-inflammatory drug (NSAID), wherein the NSAID has an anti-inflammatory activity; b) a pharmaceutically-acceptable solvent comprising a pharmaceutically-acceptable glycol ether; and c) a pharmaceutically-acceptable adjuvant comprising a mixture of pharmaceutically-acceptable lipids, wherein the ratio of the pharmaceutically-acceptable solvent to pharmaceutically-acceptable adjuvant is in a range from about 0:1 to about 1:25.

11. The solid pharmaceutical composition according to Claim 10, wherein the NSAID is Aceclofenac, Acemetacin, Actarit, Alcofenac, Alminoprofen, Amfenac, Aloxipirin, Aminophenazone, Antraphenine, Aspirin, Azapropazone, Benorilate, Benoxaprofen, Benzydamine, Butibufen, Celecoxib, Chlorthenoxacin, Choline Salicylate, Clometacin, Dexketoprofen, Diclofenac, Diflunisal, Emorfazone, Epirizole; Etodolac, Etoricoxib, Feclobuzone, Felbinac, Fenbufen, Fenclofenac, Flurbiprofen, Glafenine, Hydroxylethyl salicylate, Ibuprofen, Indometacin, Indoprofen, Ketoprofen, Ketorolac, Lactyl phenetidin, Loxoprofen, Lumiracoxib, Mefenamic acid, Meloxicam, Metamizole, Metiazinic acid, Mofebutazone, Mofezolac, Nabumetone, Naproxen, Nifenazone, Niflumic acid, Oxametacin, Phenacetin, Pipebuzone, Pranoprofen, Propyphenazone, Proquazone, Protizinic acid, Rofecoxib, Salicylamide, Salsalate, Sulindac, Suprofen, Tiaramide, Tinoridine, Tolfenamic acid, Valdecoxib, or Zomepirac.

12. The solid pharmaceutical composition according to Claim 10, wherein the pharmaceutically-acceptable glycol ether comprises diethylene glycol monomethyl ether (2-(2-methoxyethoxy)ethanol), diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol), diethylene glycol monopropyl ether (2-(2-propoxyethoxy)ethanol), diethylene glycol monoisopropyl ether (2-(2-isopropoxyethoxy)ethanol), diethylene glycol mono-n-butyl ether (2-(2-butoxyethoxy)ethanol), or any combination thereof.

13. The solid pharmaceutical composition according to Claim 10, wherein the mixture of pharmaceutically-acceptable lipids is a mixture of mono-, di-, and triglycerides and PEG fatty acid esters having a melting point of about 39°C.

14. The solid pharmaceutical composition according to Claim 10, wherein the mixture of pharmaceutically-acceptable lipids is a mixture of pharmaceutically-acceptable lipids includes mono-, di-, and triglycerides and PEG fatty acid esters having a melting point of about 43°C.

15. A liquid pharmaceutical composition comprising: a) a non-steroidal anti-inflammatory drug (NSAID), wherein the NSAID has an anti-inflammatory activity; b) a pharmaceutically-acceptable solvent comprising a pharmaceutically-acceptable glycol ether; and c) a pharmaceutically-acceptable adjuvant comprising a pharmaceutically-acceptable oil, wherein the ratio of the pharmaceutically-acceptable solvent to pharmaceutically-acceptable adjuvant is in a range from about 0:1 to about 1:25.

16. The liquid pharmaceutical composition according to Claim 15, wherein the NSAID is Aceclofenac, Acemetacin, Actarit, Alcofenac, Alminoprofen, Amfenac, Aloxipirin, Aminophenazone, Antraphenine, Aspirin, Azapropazone, Benorilate, Benoxaprofen, Benzydamine, Butibufen, Celecoxib, Chlorthenoxacin, Choline Salicylate, Clometacin, Dexketoprofen, Diclofenac, Diflunisal, Emorfazone, Epirizole; Etodolac, Etoricoxib, Feclobuzone, Felbinac, Fenbufen, Fenclofenac, Flurbiprofen, Glafenine, Hydroxylethyl salicylate, Ibuprofen, Indometacin, Indoprofen, Ketoprofen, Ketorolac, Lactyl phenetidin, Loxoprofen, Lumiracoxib, Mefenamic acid, Meloxicam, Metamizole, Metiazinic acid, Mofebutazone, Mofezolac, Nabumetone, Naproxen, Nifenazone, Niflumic acid, Oxametacin, Phenacetin, Pipebuzone, Pranoprofen, Propyphenazone, Proquazone, Protizinic acid, Rofecoxib, Salicylamide, Salsalate, Sulindac, Suprofen, Tiaramide, Tinoridine, Tolfenamic acid, Valdecoxib, or Zomepirac.

17. The liquid pharmaceutical composition according to Claim 15, wherein the pharmaceutically-acceptable glycol ether comprises diethylene glycol monomethyl ether (2-(2-methoxyethoxy)ethanol), diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol), diethylene glycol monopropyl ether (2-(2-propoxyethoxy)ethanol), diethylene glycol monoisopropyl ether (2-(2-isopropoxyethoxy)ethanol), diethylene glycol mono-n-butyl ether (2-(2-butoxyethoxy)ethanol), or any combination thereof.

18. The liquid pharmaceutical composition according to Claim 15, wherein the pharmaceutically-acceptable oil is almond oil, arachis oil, avocado oil, canola oil, castor oil, coconut oil, corn oil, cottonseed oil, grape seed oil, hazelnut oil, hemp oil, linseed oil (flax seed oil), olive oil, palm oil, peanut oil, rapeseed oil, rice bran oil, safflower oil, sesame oil, soybean oil, soya oil, sunflower oil, theobroma oil (cocoa butter), walnut oil, wheat germ oil, or any combination thereof.

19. The liquid pharmaceutical composition according to Claim 15, wherein the pharmaceutically-acceptable oil is rapessed oil, glycerol monolinoleate, theobroma oil, or any combination thereof.

20. *A liquid pharmaceutical composition comprising: a) a non-steroidal anti-inflammatory drug (NSAID),* wherein the NSAID has an anti-inflammatory activity; b) a pharmaceutically-acceptable glycol ether; c) a pharmaceutically-acceptable partially-hydrogenated fat; and d) a pharmaceutically-acceptable oil.

21. The liquid pharmaceutical composition according to Claim 20, wherein the NSAID is Aceclofenac, Acemetacin, Actarit, Alcofenac, Alminoprofen, Amfenac, Aloxipirin, Aminophenazone, Antraphenine, Aspirin, Azapropazone, Benorilate, Benoxaprofen, Benzydamine, Butibufen, Celecoxib, Chlorthenoxacin, Choline Salicylate, Clometacin, Dexketoprofen, Diclofenac, Diflunisal, Emorfazone, Epirizole; Etodolac, Etoricoxib, Feclobuzone, Felbinac, Fenbufen, Fenclofenac, Flurbiprofen, Glafenine, Hydroxylethyl salicylate, Ibuprofen, Indometacin, Indoprofen, Ketoprofen, Ketorolac, Lactyl phenetidin, Loxoprofen, Lumiracoxib, Mefenamic acid, Meloxicam, Metamizole, Metiazinic acid, Mofebutazone, Mofezolac, Nabumetone, Naproxen, Nifenazone, Niflumic acid, Oxametacin, Phenacetin, Pipebuzone, Pranoprofen, Propyphenazone, Proquazone, Protizinic acid, Rofecoxib,

Salicylamide, Salsalate, Sulindac, Suprofen, Tiaramide, Tinoridine, Tolfenamic acid, Valdecoxib, or Zomepirac.

22. *The liquid pharmaceutical composition according to Claim 15, wherein the pharmaceutically-*acceptable glycol ether comprises diethylene glycol monomethyl ether (2-(2-methoxyethoxy)ethanol), diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol), diethylene glycol monopropyl ether (2-(2-propoxyethoxy)ethanol), diethylene glycol monoisopropyl ether (2-(2-isopropoxyethoxy)ethanol), diethylene glycol mono-n-butyl ether (2-(2-butoxyethoxy)ethanol), or any combination thereof.

23. The liquid pharmaceutical composition according to Claim 20, wherein the pharmaceutically-acceptable partially-hydrogenated fat comprises glyceryl monolinoleate.

24. The liquid pharmaceutical composition according to Claim 20, wherein the pharmaceutically-acceptable oil is almond oil, arachis oil, avocado oil, canola oil, castor oil, coconut oil, corn oil, cottonseed oil, grape seed oil, hazelnut oil, hemp oil, linseed oil (flax seed oil), olive oil, palm oil, peanut oil, rapeseed oil, rice bran oil, safflower oil, sesame oil, soybean oil, soya oil, sunflower oil, theobroma oil (cocoa butter), walnut oil, wheat germ oil, or any combination thereof.

25. The liquid pharmaceutical composition according to Claim 20, wherein the pharmaceutically-acceptable oil is rapessed oil, theobroma oil, or any combination thereof.